Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adial Pharmaceuticals (ADIL) EBITDA Margin (2022 - 2024)

Adial Pharmaceuticals' EBITDA Margin history spans 3 years, with the latest figure at 63153700.0% for Q2 2024.

  • For Q2 2024, EBITDA Margin rose 6314980196.0% year-over-year to 63153700.0%; the TTM value through Dec 2024 reached 4025.8%, down 3009714.0%, while the annual FY2021 figure was 41486.48%, 39563292.0% up from the prior year.
  • EBITDA Margin for Q2 2024 was 63153700.0% at Adial Pharmaceuticals, up from 1120.52% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 63153700.0% in Q2 2024 and bottomed at 59803.6% in Q1 2022.
  • The 3-year median for EBITDA Margin is 1120.52% (2024), against an average of 12616287.81%.
  • The largest YoY upside for EBITDA Margin was 2000000000bps in 2024 against a maximum downside of 1411434bps in 2024.
  • A 3-year view of EBITDA Margin shows it stood at 59803.6% in 2022, then skyrocketed by 107bps to 3898.04% in 2023, then skyrocketed by 1620041bps to 63153700.0% in 2024.
  • Per Business Quant, the three most recent readings for ADIL's EBITDA Margin are 63153700.0% (Q2 2024), 1120.52% (Q1 2024), and 3898.04% (Q2 2023).